


THE EFFECTS OF VALACYCLOVIR ON POLYOMAVIRUS INFECTION (BKV) IN KIDNEY TRANSPLANT RECIPIENTS



K. Samadi^a, M. Ghorbansabbagh^b, V. Raesi^c, P. Marouzi^b, F. Sharifipour^b, Z. Jalambadani^a

^a Sabzevar University of Medical Sciences, Sabzevar, Iran

^b Mashhad University of Medical Sciences, Mashhad, Iran

^c Birjand University of Medical Sciences, Birjand, Iran

Abstract. Polyomavirus-associated nephropathy (PVAN) is one of the most serious infectious complications in allograft recipients, with the BK virus (BKV) being the primary etiologic agent. This study was conducted to investigate the efficacy of valacyclovir on BK virus (BKV) infection and viremia control in infected patients in Iran. This quasi-experimental study involved 21 Iranian patients. All kidney transplant recipients with a confirmed diagnosis of BKV infection based on renal biopsy and PCR were administered standard therapy (reduced doses of immunosuppressive drugs) with or without valacyclovir at a one-gram dose twice daily for one month. After collecting the data, the data was analyzed using SPSS 23. The K-S test confirmed the normality of the quantitative data. Chi-square for trend, independent-t, and Fisher's exact tests were used to examine group homogeneity in terms of socio-demographic characteristics. Before the intervention, a t-test was used to compare mean scores among the groups; and repeated measures independent sample test, pair sample test, chi square test and ANOVA. The significance level of $p < 0.05$ was considered for all tests. The mean creatinine level, mean GFR (Glomerular Filtration Rate) level, and median viral load in the serum were not significantly different between the two groups at the time of graft rejection diagnosis. One month after treatment, the serum viral load decreased in 90.9% of patients in the intervention group and 50% of patients in the control group, with the difference being statistically significant ($p = 0.038$). Also, in the two-month review, the results showed that the reduction of the virus serum load level was observed in 81.8% of patients in the intervention group and 40% of patients in the control group, and this difference was statistically significant ($p = 0.049$). Mean age, body mass index, and transplant duration were comparable between the two groups. Neither creatinine nor GFR levels differed significantly between the two groups after the intervention ($p = 0.557$ and $p = 0.387$). Valacyclovir can effectively reduce the serum viral load in BKV-infected kidney transplant recipients. This reduction, however, is not accompanied by an improvement in renal function or prevention of rejection.

Key words: kidney transplant, polyomavirus infection, valacyclovir.

ВЛИЯНИЕ ВАЛАЦИКЛОВИРА НА ПОЛИОМАВИРУСНУЮ ИНФЕКЦИЮ У РЕЦИПИЕНТОВ ТРАНСПЛАНТАЦИИ ПОЧЕК

Самади К.¹, Горбансаббах М.², Раези В.³, Марузи П.², Шарифиپур Ф.², Джаламбадани З.¹

¹ Сабзеварский университет медицинских наук, г. Сабзевар, Иран

² Мешхедский университет медицинских наук, г. Мешхед, Иран

³ Бирджандский университет медицинских наук, г. Бирджанд, Иран

Резюме. Нефропатия, ассоциированная с полиомавирусом (ПВАН), является одним из самых серьезных инфекционных осложнений у реципиентов аллотрансплантата, причем основным этиологическим агентом

Адрес для переписки:

Зейнаб Джаламбадани
E-mail: jalambadaniz@gmail.com; jalambadaniz@medsab.ac.ir
Фарзана Шарифиپур
E-mail: sharifipourf@mums.ac.ir
Тел.: 05144018301.

Contacts:

Zeinab Jalambadani
E-mail: jalambadaniz@gmail.com; jalambadaniz@medsab.ac.ir
Farzaneh Sharifipour
E-mail: sharifipourf@mums.ac.ir
Phone: 05144018301.

Для цитирования:

Самади К., Горбансаббах М., Раези В., Марузи П., Шарифипур Ф., Джаламбадани З. Влияние валацикловира на полиомавирусную инфекцию у реципиентов трансплантации почек // Инфекция и иммунитет. 2025. Т. 15, № 2. С. 341–347. doi: 10.15789/2220-7619-TEO-17712

© Samadi K. et al., 2025

Citation:

Samadi K., Ghorbansabbagh M., Raesi V., Marouzi P., Sharifipour F., Jalambadani Z. The effects of valacyclovir on polyomavirus infection (BKV) in kidney transplant recipients // Russian Journal of Infection and Immunity = Infektsiya i immunitet, 2025, vol. 15, no. 2, pp. 341–347. doi: 10.15789/2220-7619-TEO-17712

DOI: <http://dx.doi.org/10.15789/2220-7619-TEO-17712>

является вирус ВК (ВКВ). Настоящее исследование было проведено с целью изучения эффективности валацикловира при ВКВ-инфекции и контроле виремии у инфицированных пациентов в Иране. В поведенном квазиэкспериментальном исследовании приняли участие 21 пациент из Ирана. Всем реципиентам почечного трансплантата с подтвержденным диагнозом инфекции ВКВ на основе биопсии почки и ПЦР назначалась стандартная терапия (сниженные дозы иммунодепрессантов) с валацикловиром в дозе 1 г 2 раза в день в течение 1 месяца или без него. Анализ полученных данных был проведен с помощью программы SPSS 23. Тест К-S подтвердил нормальность количественных распределений данных. Для изучения однородности группы по социально-демографическим характеристикам использовались методы хи-квадрат для тренда, независимый t-критерий и точный метод Фишера. Перед вмешательством использовался t-тест для сравнения средних баллов среди групп; проведена повторная оценка независимого выборочного теста, парного выборочного теста, критерия хи-квадрат и дисперсионного анализа. Для всех тестов был установлен уровень достоверности $p < 0,05$. Средний уровень креатинина, средний уровень скорости клубочковой фильтрации (СКФ) и медианная вирусная нагрузка в сыворотке существенно не различались между двумя группами на момент постановки диагноза отторжения трансплантата. Через месяц после лечения вирусная нагрузка в сыворотке статистически достоверно снизилась у 90,9% пациентов в группе вмешательства и у 50% пациентов в контрольной группе ($p = 0,038$). Кроме того, в ходе двухмесячного мониторинга показано, что достоверное снижение уровня вирусной нагрузки в сыворотке наблюдалось у 81,8% пациентов в группе вмешательства и у 40% пациентов в контрольной группе ($p = 0,049$). Средний возраст, индекс массы тела и продолжительность трансплантации были сопоставимы между двумя группами. Уровни креатинина и уровни СКФ не различались существенно между двумя группами после вмешательства ($p = 0,557$ и $p = 0,387$). Валацикловир может эффективно снижать вирусную нагрузку в сыворотке у реципиентов почечного трансплантата, инфицированных ВКВ. Однако это снижение не сопровождается улучшением функции почек или предотвращением отторжения.

Ключевые слова: трансплантация почки, полиомавирусная инфекция, валацикловир.

Introduction

BK polyomavirus is a circular, double-stranded DNA virus from the polyomavirus family. Based on DNA sequence variations, BK polyomavirus can be divided into six subtypes or genotypes. Genotype I is the most frequent worldwide (80%), followed by Genotype IV (15%). BK polyomavirus is ubiquitous in the population, with > 80% of adults being seropositive, with infection typically being acquired during childhood [1].

Polyomavirus-associated nephropathy (PVAN) is one of the most serious infectious complications in allograft recipients, with the BK virus (BKV) being the primary etiologic agent. It is characterized by cytopathic changes in epithelial and glomerular cells in the transplanted kidney [1, 8, 12, 15, 24, 25, 28, 32]. Approximately 30–50% of transplant recipients develop BKV nephropathy due to the reactivation of latent polyomaviruses in the urinary tract [14, 15, 28].

The common characteristics of early events in the pathogenesis of BKV nephropathy and the severe clinical overlap necessitate preventive treatment strategies to impede disease progression and obvious renal damage, even before the diagnosis is confirmed by biopsy. Validated protocols for patient screening and preventive therapies are now included in the recommendations for graft management following renal transplantation [4, 11, 13, 15, 19, 26, 36, 37].

There are too many clinical indications for renal biopsy leading to a histological diagnosis of definitive PVAN, which are contingent on the standard of each medical facility, the set of treatment measures, and the availability of resources. Some kidney transplant

facilities typically perform a biopsy on patients with viremia or possible PVAN to ensure the diagnosis of PVAN. Additionally, renal biopsy allows for the determination of the severity of acute and chronic kidney tissue damage, as well as the evaluation of other kidney diseases that may affect allograft functionality and patient management [13, 15, 27].

The biopsy is especially important when we consider that quantitative PCR tests are not standard for evaluating BK viremia and that BK viremia titers only predict the degree of viral kidney damage in a limited way and thus cannot provide diagnostic certainty [2, 21, 24, 28, 39].

In the vast majority of cases, kidney allograft biopsies are performed to diagnose unexplained and unspecified clinical disorders in the functioning of transplanted kidneys, which can be caused by underlying BK nephropathy. Definitive PVAN may also be found unexpectedly in surveillance biopsies of patients with stable grafts [5, 24, 35].

Indeed, biopsies of kidney allografts are performed under various clinical conditions and for various indications, during which morphological evidence of PVAN may be observed. In developed countries, the incidence of biopsy-proven PVAN ranges between 5% and 6%, although its prevalence varies considerably between institutions [2, 39].

The highest rate of definitive PVAN is observed in kidney transplants with ABO-incompatible donors and recipients (18%) and after desensitization in highly sensitized allograft recipients (20%) [9, 39]. The Renal Pathology Society, the Banff Working Group on Liver Allograft Pathology, and the Nephrology Working Group of the European

Society of Pathology have proposed a standard approach to classifying this disorder, which has been supported and validated by studies [29].

Approaches such as reducing the dose of suppressive drugs to the use of antiviral treatments based on the severity of viremia and the occurrence of evidence of nephropathy have been introduced [40]. Brincidofovir is a prodrug of cidofovir that has been used so far, although limited results of its success rate have been reported [30]. IVIG products containing high titers of BK virus-neutralizing antibodies have been used as adjuvant therapy and increase the virus clearance rate from serum [22, 41].

So far, there is no consensus regarding the definitive treatment of BK virus nephropathy in kidney transplant patients, and this research was conducted for the first time to investigate the effect of valacyclovir on treating BKV infection and controlling viremia in infected patients.

Materials and methods

This quasi-experimental study evaluated 21 patients with a confirmed BKV infection (PCR test results) who were referred to Hospitals in Iran. The sample size was calculated using the formula for a quasi-experimental survey [21].

In this study, random allocation was not used. With a margin of error = 0.05 and = 10%, an expected power of 90%, a Z value of 1.28. The participants were 21 Iranian patients.

$$n = \frac{(z_{1-\alpha/2} + z_{1-\beta})^2 (d_1^2 + d_2^2)}{(\mu_1 - \mu_2)^2}$$

Evidence of BKV nephropathy and BKV viremia constituted the inclusion criteria, while exclusion criteria comprised lack of consent, a history of hypersensitivity reactions to valacyclovir, and the incidence of complications upon valacyclovir therapy.

Ethical approval. Ethical approval in this study, all procedures performed on human samples were conducted following the relevant guidelines and regulations of the Helsinki Declaration. The study protocol was approved by the Research Ethics Committee (IR.MUMS.MEDICAL.REC.1399.031) in Mashhad Iran.

Study groups. In addition to intravenous immunoglobulin (IVIG), patients received standard transplant drug dose reduction and modification in case required. The control group received the standard routine treatment, while the intervention group received one gram of valacyclovir (Abidi Company) twice daily in addition to the standard treatment. The drug dosage was modified according to creatinine clearance. PCR was reiterated one and two months after treatment initiation to assess and compare viremia levels between groups. Uniplex Real-time PCR on 21 virus DNA samples extracted from plasma based on the ISEX version of the kits JC Virus

PCR and BK Virus PCR related Videňská, Czech Republic (GeneProof) was performed.

There were not any adverse effects of Valacyclovir noticed during treatment. A decrease in viral load was defined as a decline in the serum level of the viral genome after treatment relative to the baseline value at the time of diagnosis. Based on the objectives of the research project, the researcher designed a checklist that included gender, age, height, weight, body mass index (BMI), cause of renal failure, duration of transplant, coinfection with CMV, polyomavirus PCR result (before treatment, one month after treatment, and two months after treatment). All kidney transplant patients were infected with BKV PCR (BKV or kidney biopsy proven at the time of study with interstitial fibrosis and tubular atrophy (IFTA < 20). Serum creatinine level prior to and two months after treatment, GFR prior to and two months after treatment, and the study group.

Data analyses. After collecting the data, the data was analyzed using SPSS 23. The K-S test confirmed the normality of the quantitative data. Chi-square for trend, independent-t, and Fisher's exact tests were used to examine group homogeneity in terms of socio-demographic characteristics. Before the intervention, a t-test was used to compare mean scores among the groups; and repeated measures independent sample test, pair sample test, chi square test and ANOVA. The significance level of $p < 0.05$ was considered for all tests.

Results

A total of 21 patients were examined, 11 patients were included in the intervention group and 10 patients were included in the control group. The average age in intervention group patients was 39 ± 10.4 years and in control group patients was 32 ± 8.2 years, the observed difference was not significant ($p = 0.104$). The average height in the intervention and control groups was 164.5 ± 7.9 and 166.9 ± 7.5 cm, respectively, and the average weight in the intervention and control groups was 63 ± 15.5 and 66 ± 10.2 kg, respectively. None of the observed differences were significant ($p = 0.496$ and 0.612 , respectively). The average body mass index in the intervention group was 24.1 ± 6.7 kg/m² and in the control group it was 24.7 ± 3.1 kg/m², so there was no significant difference between the two groups ($p = 0.804$). Mean age, height, BMI, and weight did not differ significantly between the control and intervention groups before of intervention, as displayed in Table 1 ($p > 0.05$). In both groups, the median transplant duration was 12 months.

According to the results of Table 2, the only symptom that led to the diagnosis of transplant rejection in both groups was an increase in serum creatinine levels ($p < 0.05$). Besides, this study did not detect CMV coinfection in any of the examined patients in both groups ($p > 0.05$).

Table 1. Characteristics of the participants in the study according to the studied groups before of intervention

Parameter	Intervention Group Mean±SD	Control Group Mean±SD	P-value
Age (years)	39±10.4	32±8.2	p = 0.104*
Height (cm)	164.5±7.9	166.9±7.5	p = 0.496*
Weight (kg)	63±15.5	66±10.2	p = 0.612*
Body mass index (kg/m ²)	24.1±6.7	24.7±3.1	p = 0.804*
Transplant time (month)	12	12	p = 0.918**

Note. The independent t-test result.

The only symptom that led to the diagnosis of transplant rejection in the patients of both groups was the increase in serum creatinine. The result of this investigation showed that the simultaneous infection with CMV was not observed in any of the examined patients. Also, when transplant rejection was diagnosed, there was no significant difference between the two groups in the average level of creatinine, average level of GFR and average level of viral load in serum.

The mean creatinine level, mean GFR level, and median viral load in the serum were not significantly different between the two groups at the time of graft rejection diagnosis. One month after treatment, the serum viral load decreased in 90.9% of patients in the intervention group and 50% of patients in the control group, with the difference being statistically significant ($p = 0.038$). In addition, the two-month assessment revealed that 81.8% of patients in the intervention group and 40% in the control group experienced a reduction in serum viral load, which is statistically significant ($p = 0.049$). Creatinine and GFR levels did not differ significantly ($p = 0.577$ and $p = 0.387$) between the two groups at the post-intervention examination (Table 3).

Discussion

According to the findings of this study, a significant decline in serum viral load was observed one month after treatment with valacyclovir along with routine treatments (90.9% in the intervention group and 50% in the control group) ($p = 0.038$). Two months

after the intervention, too, there was a significant reduction in serum viral load in the intervention group relative to the control group (81.8% in the intervention group and 40% in the control group) ($p = 0.049$).

According to the study findings, the administration of valacyclovir in BKV-infected kidney transplant recipients can reduce the serum viral load. There is currently no consensus on the definitive treatment for BKV nephropathy in kidney transplant recipients. Approaches ranging from lowering the dose of suppressive drugs to using antiviral treatments have been utilized based on the severity of viremia and evidence of nephropathy [39].

If the number of BKV serum copies is below 10 000, a dose reduction of immunosuppressive drugs will suffice. If there are more than 10 000 copies, a common first step is reducing the calcineurin inhibitor dose by 25 to 50 percent. Changing prescription drugs such as tacrolimus to cyclosporine A has been associated with improved outcomes [7], although using this strategy increases the likelihood of acute transplant rejection [10]. If the number of virus copies in the serum remains elevated despite these interventions, the dose of mycophenolate mofetil should be reduced by 50 percent, or the drug should be discontinued and replaced with mTOR inhibitors [3, 6]. Changing the treatment from mycophenolate mofetil to leflunomide is an additional strategy with typically positive outcomes [15, 16, 42]. If the treatments above fail or in cases of resistance, cidofovir is the only treatment option, although its nephrotoxicity limits its administration [17, 18, 20]. Brincidofovir is a prodrug of cidofovir that has

Table 2. Comparison of gender and etiology of kidney failure per study group before of intervention

Parameter		Intervention group Frequency (Percentage)	Control group Frequency (Percentage)	P-value
Gender	Male	5 (45.5)	3 (30)	$p^* = 0.659$
	Female	6 (54.5)	7 (70)	
Etiology of kidney failure	FSGS	1 (9.1)	(0) 0	$p^{**} = 0.210$
	Nephrotic syndromes	2 (18.2)	6 (60)	
	DM	2 (18.2)	6 (60)	
	Hypertension	2 (18.2)	1 (10)	
	PKD	1 (9.1)	(0) 0	
	Preeclampsia	1 (9.1)	(0) 0	
	Pyelonephritis	2 (18.2)	1 (10)	
	Reflux nephropathy	0 (0)	2 (20)	

Note. DM: diabetes mellitus, FSGS: Focal segmental glomerulosclerosis, D: Polycystic kidney disease. *Chi square; **One-way Anova.

Table 3. Comparing the frequency distribution of reductions in the serum viral load levels in the study groups

Variables (Qualitative)		Intervention Group Frequency (percentage)	Control Group Frequency (percentage)	P-value
One month after treatment	No	1 (9.1)	5 (50)	p = 0.038*
	Yes	10 (9.90)	5 (50)	
Two months after treatment	No	2 (18.2)	6 (60)	p = 0.049*
	Yes	9 (81.8)	4 (40)	
Creatinine level		2.2	2.2	3.2
GFR level		29.5	29.5	24.4
Serum viral load after one month		130 000	130 000	1 796 125
Serum viral load after two months		4900	4900	935 875
Variables (Quantitative)		Intervention Group (Mean±standard deviation)	Control Group (Mean±standard deviation)	P-value
Creatinine level		2.1±0.7	1.9±0.5	p = 0.437***
GFR level		35±3.11	42.8±17.1	p = 0.231**
Serum viral load		479 500	194 675	p = 0.512**

Note. *Based on the result of Fisher's exact test; **based on the result of the Mann-Whitney test; ***based on the independent t-test result.

been used thus far, although there are only a few reports of its success rate [30]. In Reischig, Tomas study Valganciclovir shows no superior efficacy in cytomegalovirus DNAemia prevention compared with valganciclovir prophylaxis. However, the risk of biopsy-proven acute rejection is higher with valganciclovir [34].

IVIG products with high BKV neutralizing antibody titers are used as an adjuvant to accelerate virus clearance from [22, 33, 38, 41].

There is no independent evidence regarding the role of valganciclovir in BK nephropathy and viral viremia in transplant patients. Park et al. (2020) [31] investigated the effect of prophylactic valganciclovir administration on the incidence of cytomegalovirus infection in patients undergoing kidney transplantation. In this study, this disorder was diagnosed in 1 out of 46 patients in the combined treatment group and 3 out of 107 patients in the single drug treatment group; however, the observed difference was not statistically significant. Valganciclovir prophylaxis effectively decreased the occurrence of CMV infection in KTRs in their study. Therefore, they should use valganciclovir prophylaxis for 3 months in KTRs with risk factors such as old age, thymoglobulin induction, and delayed graft function.

As a strength, this controlled study was conducted with two groups that were similar in basic information and included all new patients with transplant rejection, thereby eliminating selection bias.

Limitation

The primary limitation of this study is the small sample size, which restricts the generalizability of its findings. Also, non-random sampling and the two-month follow-up, particularly in the absence of improvement in kidney function, limits the interpretation of the findings regarding the efficacy of this drug on transplantation's ultimate outcome (as the main goal of treating BKV infection).

Conclusion

Based on the findings of this study, in kidney transplant recipients with BKV infection, using valganciclovir can lower the amount of virus in the blood. However, this treatment is neither lead to better kidney function nor prevent rejection of the transplanted kidney based on the results of this study. It is suggested that future research be conducted as multicenter clinical trials with large sample sizes, longer follow-ups, and determination of the graft's outcome.

Acknowledgments

The authors would like to thank all the participants who kindly cooperated in the process of the study. We also want to thank the Deputy of Research and Technology of Mashhad University of Medical Sciences, Mashhad, Iran.

References

1. Binet I., Nicleleit V., Hirsch H.H., Prince O., Dalquen P., Gudat F., Mihatsch M.J., Thiel G. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. *Transplantation*, 1999, vol. 67, no. 6, pp. 918–922. doi: 10.1097/00007890-199903270-00022
2. Boan P., Hewison C., Swaminathan R., Irish A., Warr K., Sinniah R., Pryce T.M., Flexman J. Optimal use of plasma and urine BK viral loads for screening and predicting BK nephropathy. *BMC Infect.*, 2016, vol. 16: 342. doi: 10.1186/s12879-016-1652-6
3. Bowman L.J., Brueckner A.J., Doligalski C.T. The role of mTOR inhibitors in the management of viral infections: a review of current literature. *Transplantation*, 2018, vol. 102, no. 2, pp. 50–59. doi: 10.1097/tp.0000000000001777
4. Brennan D.C., Agha I., Bohl D.L., Schnitzler M.A., Hardinger K.L., Lockwood M., Torrence S., Schuessler R., Roby T., Gaudreault-Keener M., Storch G.A. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. *Am. J. Transplant.*, 2005, vol. 5, no. 3, pp. 582–594. doi: 10.1111/j.1600-6143.2005.00742.x

5. Buehrig C.K., Lager D.J., Stegall M.D., Kreps M.A., Kremers W.K., Gloor J.M., Schwab T.R., Velosa J.A., Fidler M.E., Larson T.S., Griffin M.D. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. *Kidney Int.*, 2003, vol. 64, no. 2, pp. 665–673. doi: 10.1046/j.1523-1755.2003.00103.x
6. Bussalino E., Marsano L., Parodi A., Russo R., Massarino F., Ravera M., Gaggero G., Fontana I., Garibotto G., Zaza G., Stallone G., Paoletti E. Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study. *J. Nephrol.*, 2020. doi: 10.1007/s40620-020-00777-2
7. Chen X.T., Li J., Deng R.H., Yang S.C., Chen Y.Y., Chen P.S., Wang Z.Y., Huang Y., Wang C.X., Huang G. The therapeutic effect of switching from tacrolimus to low-dose cyclosporine A in renal transplant recipients with BK virus nephropathy. *Biosci. Rep.*, 2019, vol. 39, no. 2. doi: 10.1042/bsr20182058
8. Drachenberg C.B., Beskow C.O., Cangro C.B., Bourquin P.M., Simsir A., Fink J., Weir M.R., Klassen D.K., Bartlett S.T., Papadimitriou J.C. Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. *Hum. Pathol.*, 1999, vol. 30, no. 8, pp. 970–977. doi: 10.1016/s0046-8177(99)90252-6
9. Gabardi S., Townsend K., Martin S.T., Chandraker A. Evaluating the impact of pre-transplant desensitization utilizing a plasmapheresis and low-dose intravenous immunoglobulin protocol on BK viremia in renal transplant recipients. *Transpl. Infect. Dis.*, 2013, vol. 15, no. 4, pp. 361–368. doi: 10.1111/tid.12087
10. Gard L., van Doesum W., Niesters H.G.M., van Son W.J., Diepstra A., Stegeman C.A., Groen H., Riezebos-Brilman A., Sanders J.S. A delicate balance between rejection and BK polyomavirus associated nephropathy; a retrospective cohort study in renal transplant recipients. *PLoS One*, 2017, vol. 12, no. 6: e0178801. doi: 10.1371/journal.pone.0178801
11. Hardinger K.L., Koch M.J., Bohl D.J., Storch G.A., Brennan D.C. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. *Am. J. Transplant.*, 2010, vol. 10, no. 2, pp. 407–415. doi: 10.1111/j.1600-6143.2009.02952.x
12. Hirsch H.H. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. *Am. J. Transplant.*, 2002, vol. 2, no. 1, pp. 25–30. doi: 10.1034/j.1600-6143.2002.020106.x
13. Hirsch H.H., Brennan D.C., Drachenberg C.B., Ginevri F., Gordon J., Limaye A.P., Mihatsch M.J., Nicleit V., Ramos E., Randhawa P., Shapiro R., Steiger J., Suthanthiran M., Trofe J. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. *Transplantation*, 2005, vol. 79, no. 10, pp. 1277–1286. doi: 10.1097/01.tp.0000156165.83160.09
14. Hirsch H.H., Knowles W., Dickenmann M., Passweg J., Klimkait T., Mihatsch M.J., Steiger J. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. *N. Engl. J. Med.*, 2002, vol. 347, no. 7, pp. 488–496. doi: 10.1056/NEJMoa020439
15. Hirsch H.H., Randhawa P. BK polyomavirus in solid organ transplantation. *Am. J. Transplant.*, 2013, vol. 13, no. 4, pp. 179–188. doi: 10.1111/ajt.12110
16. Josephson M.A., Gillen D., Javaid B., Kadambi P., Meehan S., Foster P., Harland R., Thistlethwaite R.J., Garfinkel M., Atwood W., Jordan J., Sadhu M., Millis M.J., Williams J. Treatment of renal allograft polyoma BK virus infection with leflunomide. *Transplantation*, 2006, vol. 81, no. 5, pp. 704–710. doi: 10.1097/01.tp.0000181149.76113.50
17. Kadambi P.V., Josephson M.A., Williams J., Corey L., Jerome K.R., Meehan S.M., Limaye A.P. Treatment of refractory BK virus-associated nephropathy with cidofovir. *Am. J. Transplant.*, 2003, vol. 3, no. 2, pp. 186–191. doi: 10.1034/j.1600-6143.2003.30202.x
18. Keller L.S., Peh C.A., Nolan J., Bannister K.M., Clarkson A.R., Faull R.J. BK transplant nephropathy successfully treated with cidofovir. *Nephrol. Dial. Transplant.*, 2003, vol. 18, no. 5, pp. 1013–1014. doi: 10.1093/ndt/gfg061
19. Kuypers D.R. Management of polyomavirus-associated nephropathy in renal transplant recipients. *Nat. Rev. Nephrol.*, 2012, vol. 8, no. 7, pp. 390–402. doi: 10.1038/nrneph.2012.64
20. Kuypers D.R., Vandooren A.K., Lerut E., Evenepoel P., Claes K., Snoeck R., Naesens L., Vanrenterghem Y. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. *Am. J. Transplant.*, 2005, vol. 5, no. 8, pp. 1997–2004. doi: 10.1111/j.1600-6143.2005.00980.x
21. Maciejewski M.L. Quasi-experimental design. *Biostatistics and Epidemiology*, 2020, vol. 4, no. 1, pp. 38–47. doi: 10.1080/24709360.2018.1477468
22. Milstone A., Vilchez R.A., Geiger X., Fogo A.B., Butel J.S., Dummer S. Polyomavirus simian virus 40 infection associated with nephropathy in a lung-transplant recipient. *Transplantation*, 2004, vol. 77, no. 7, pp. 1019–1024. doi: 10.1097/01.tp.0000119156.52197.ca
23. Moon J., Chang Y., Shah T., Min D.I. Effects of intravenous immunoglobulin therapy and Fc gamma receptor polymorphisms on BK virus nephropathy in kidney transplant recipients. *Transpl. Infect. Dis.*, 2020, vol. 22, no. 4: e13300. doi: 10.1111/tid.13300
24. Nankivell B.J., Renthawa J., Sharma R.N., Kable K., O'Connell P.J., Chapman J.R. BK virus nephropathy: histological evolution by sequential pathology. *Am. J. Transplant.*, 2017, vol. 17, no. 8, pp. 2065–2077. doi: 10.1111/ajt.14292
25. Nicleit V., Hirsch H.H., Binet I.F., Gudat F., Prince O., Dalquen P., Thiel G., Mihatsch M.J. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. *J. Am. Soc. Nephrol.*, 1999, vol. 10, no. 5, pp. 1080–1089. doi: 10.1681/ASN.V1051080
26. Nicleit V., Hirsch H.H., Zeiler M., Gudat F., Prince O., Thiel G., Mihatsch M.J. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. *Nephrol. Dial.*, 2000, vol. 15, no. 3, pp. 324–332. doi: 10.1093/ndt/15.3.324
27. Nicleit V., Mihatsch M.J. Polyomavirus nephropathy in native kidneys and renal allografts: an update on an escalating threat. *Transpl. Int.*, 2006, vol. 19, no. 12, pp. 960–973. doi: 10.1111/j.1432-2277.2006.00360.x
28. Nicleit V., Singh H.K. Polyomaviruses and disease: is there more to know than viremia and viruria? *Curr. Opin. Organ. Transplant.*, 2015, vol. 20, no. 3, pp. 348–358. doi: 10.1097/mot.0000000000000192
29. Nicleit V., Singh H.K., Randhawa P., Drachenberg C.B., Bhatnagar R., Bracamonte E., Chang A., Chon W.J., Dadhania D., Davis V.G., Hopfer H., Mihatsch M.J., Papadimitriou J.C., Schaub S., Stokes M.B., Tungekar M.F., Seshan S.V. The Banff Working Group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations. *J. Am. Soc. Nephrol.*, 2018, vol. 29, no. 2, pp. 680–693. doi: 10.1681/asn.2017050477

30. Papanicolaou G.A., Lee Y.J., Young J.W., Seshan S.V., Boruchov A.M., Chittick G., Momméja-Marín H., Glezerman I.G. Brincidofovir for polyomavirus-associated nephropathy after allogeneic hematopoietic stem cell transplantation. *Am. J. Kidney Dis.*, 2015, vol. 65, no. 5, pp. 780–784. doi: 10.1053/j.ajkd.2014.11.020
31. Park W.Y., Kim Y., Paek J.H., Jin K., Park S.B., Han S. Effectiveness of valganciclovir prophylaxis against the occurrence of cytomegalovirus infection in kidney transplant recipients. *Korean J. Transplant.*, 2020, vol. 34, no. 1, pp. 15–23. doi: 10.4285/kjt.2020.34.1.15
32. Purighalla R., Shapiro R., McCauley J., Randhawa P. BK virus infection in a kidney allograft diagnosed by needle biopsy. *Am. J. Kidney Dis.*, 1995, vol. 26, no. 4, pp. 671–673. doi: 10.1016/0272-6386(95)90608-8
33. Randhawa P., Pastrana D.V., Zeng G., Huang Y., Shapiro R., Sood P., Puttarajappa C., Berger M., Hariharan S., Buck C.B. Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK. *Am. J. Transplant.*, 2015, vol. 15, no. 4, pp. 1014–1020. doi: 10.1111/ajt.13083
34. Reischig T., Kacer M., Jindra P., Hes O., Lysak D., Bouda M. Randomized trial of valganciclovir versus valganciclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. *Clin. J. Am. Soc. Nephrol.*, 2015, vol. 10, no. 2, pp. 294–304. doi: 10.2215/CJN.07020714
35. Renoult E., Coutlee F., Paquet M., St Louis G., Girardin C., Fortin M.C., Cardinal H., Levesque R., Schurch W., Latour M., Barama A., Hebert M.J. Evaluation of a preemptive strategy for BK polyomavirus-associated nephropathy based on prospective monitoring of BK viremia: a kidney transplantation center experience. *Transplant. Proc.*, 2010, vol. 42, no. 10, pp. 4083–4087. doi: 10.1016/j.transproceed.2010.09.024
36. Schaub S., Hirsch H.H., Dickenmann M., Steiger J., Mihatsch M.J., Hopfer H., Mayr M. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. *Am. J. Transplant.*, 2010, vol. 10, no. 12, pp. 2615–2623. doi: 10.1111/j.1600-6143.2010.03310.x
37. Seifert M.E., Gunasekaran M., Horwedel T.A., Daloul R., Storch G.A., Mohanakumar T., Brennan D.C. Polyomavirus reactivation and immune responses to kidney-specific self-antigens in transplantation. *J. Am. Soc. Nephrol.*, 2017, vol. 28, no. 4, pp. 1314–1325. doi: 10.1681/asn.2016030285
38. Sener A., House A.A., Jevnikar A.M., Boudville N., McAlister V.C., Muirhead N., Rehman F., Luke P.P. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. *Transplantation*, 2006, vol. 81, no. 1, pp. 117–120. doi: 10.1097/01.tp.0000181096.14257.c2
39. Sharif A., Alachkar N., Bagnasco S., Geetha D., Gupta G., Womer K., Arend L., Racusen L., Montgomery R., Kraus E. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. *Clin. J. Am. Soc. Nephrol.*, 2012, vol. 7, no. 8, pp. 1320–1327. doi: 10.2215/CJN.00770112
40. Sharma R., Zachariah M.B. BK Virus nephropathy: prevalence, impact and management strategies. *Int. J. Nephrol. Renovasc. Dis.*, 2020, vol. 13, pp. 187–192. doi: 10.2147/IJNRD.S236556
41. Vu D., Shah T., Ansari J., Naraghi R., Min D. Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients. *Transplant. Proc.*, 2015, vol. 47, no. 2, pp. 394–398. doi: 10.1016/j.transproceed.2015.01.012
42. Williams J.W., Javaid B., Kadambi P.V., Gillen D., Harland R., Thistlewaite J.R., Garfinkel M., Foster P., Atwood W., Millis J.M., Meehan S.M., Josephson M.A. Leflunomide for polyomavirus type BK nephropathy. *N. Engl. J. Med.*, 2005, vol. 352, no. 11, pp. 1157–1158. doi: 10.1056/nejm200503173521125

Авторы:

Самади К., ассистент кафедры внутренней медицины (нефрология), медицинский факультет, Сабзеварский университет медицинских наук, г. Сабзевар, Иран;
Горбансаббах М., доцент кафедры внутренней медицины (нефрология), медицинский факультет, Мешхедский университет медицинских наук, г. Мешхед, Иран;
Раези В., ассистент кафедры внутренней медицины (нефрология), медицинский факультет, Бирджандский университет медицинских наук, г. Бирджанд, Иран;
Марузи П., доцент кафедры медицинских информационных технологий медицинской документации (биостатистика), Школа парамедицинских наук, Мешхедский университет медицинских наук, г. Мешхед, Иран;
Шарифпур Ф., доцент кафедры внутренней медицины (нефрология), медицинский факультет, Мешхедский университет медицинских наук, г. Мешхед, Иран;
Джаламбадани З., доцент кафедры общественной медицины (санитарное просвещение и пропаганда здорового образа жизни), Медицинский факультет, Сабзеварский университет медицинских наук, г. Сабзевар, Иран; доцент кафедры санитарного просвещения и пропаганды здорового образа жизни, Исследовательский центр неинфекционных заболеваний, Медицинский факультет, Сабзеварский университет медицинских наук, г. Сабзевар, Иран.

Authors:

Samadi K., Assistant Professor of Nephrology, Department of Internal Medicine, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran;
Ghorbansabbagh M., Associate Professor of Nephrology, Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;
Raesi V., Assistant Professor of Nephrology, Department of Internal Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran;
Marouzi P., Assistant Professor of Biostatistics, Department of Health Information Technology and Medical Records, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran;
Sharifipour F., Associate Professor of Nephrology, Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;
Jalambadani Z., Assistant Professor of Health Education and Promotion, Department of Community Medicine, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran; Assistant Professor of Health Education and Promotion, Non-Communicable Diseases Research Center, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.

Поступила в редакцию 20.07.2024
 Отправлена на доработку 02.09.2024
 Принята к печати 09.09.2024

Received 20.07.2024
 Revision received 02.09.2024
 Accepted 09.09.2024